MolecularHealth Adds Chief Medical Officer to New Management Team Dr. Shelly Gunn brings deep expertise in diagnostic molecular genetics to MolecularHealth’s executive leadership Business Wire THE WOODLANDS, Texas -- September 30, 2013 In a continuation of its plan to commercialize its automated genetic diagnostic platform for cancer care in the first quarter of 2014, MolecularHealth announced that it has hired Shelly Gunn, M.D., Ph.D. to serve as its chief medical officer. The announcement comes on the heels of the installation of four key members of the company’s U.S. management team. Dr. Gunn comes to MolecularHealth with an extensive background in diagnostic molecular genetics, and is recognized as one of the world’s leading experts in the clinical application of array comparative genomic hybridization (aCGH) technology, specifically in the areas of breast cancer and hematologic malignancies. She earned a combined M.D./Ph.D. degree from The University of Texas Health Science Center at San Antonio (UTHSCSA) Medical School and Graduate School of Biomedical Sciences, where she also completed her clinical pathology residency. Prior to joining MolecularHealth, Dr. Gunn founded Oncopath Laboratory, a genomic pathology reference laboratory located at the START Center for Cancer Care in San Antonio, Texas. “Dr. Gunn has spent her career focusing on using genomic testing to provide personalized care to cancer patients, which aligns her experience perfectly with our mission,” said Lloyd Everson, M.D., CEO of MolecularHealth. “As we build out our executive leadership, we are looking for key industry veterans who bring an extremely high level of expertise in molecular diagnostics, CLIA lab operations, genomics, and the actionable interpretation of these results for cancer patients. Dr. Gunn’s background and stature in the community will be a huge asset to our team.” Backed by Dietmar Hopp, co-founder and former chairman and CEO of SAP, MolecularHealth’s genetic diagnostic platform is the result of more than eight years of development by a multidisciplinary team of doctors, scientists and IT experts in Heidelberg, Germany. The company is preparing for the commercial launch of its end-to-end service offering, which walks patients and their healthcare providers through the molecular diagnostic process—collecting tumor samples, analyzing the samples in a CLIA-certified lab, and interpreting the results using a unique analytics platform—all to generate safer and more targeted cancer treatment choices. As part of its offering, MolecularHealth will provide patients, oncologists and pathologists with complete logistical support, including on-call consultations with Dr. Gunn and the Molecular Health pathology team and help navigating insurance reimbursement for recommended treatments. Dr. Gunn said, “The field of molecular diagnostics promises to revolutionize the treatment of cancer, providing better patient outcomes and quality of life. MolecularHealth’s end-to-end solution allows doctors to understand the role that genetics plays in the onset and progression of cancer, providing them with information drawn from an extensive library of clinical research. I’m excited to be a part of this breakthrough company, offering a breakthrough platform in an effort to improve human health.” ABOUT MOLECULARHEALTH MolecularHealth delivers on the promise of personalized, precision medicine. By using advanced information technologies to sift through terabytes of genetic and molecular test findings in a fraction of the time needed for current manual analysis, MolecularHealth provides doctors and patients with faster, more accurate insights into the role genes play in the progression and treatment of an individual’s cancer. Eight years in development by a multidisciplinary team of doctors, scientists and IT experts, MolecularHealth works in partnership with some of the world’s leading healthcare and information technology companies, including the University of Texas MD Anderson Cancer Center, SAP AG, and the U.S. Food and Drug Administration (FDA). The company has headquarters in The Woodlands, Texas; Basel, Switzerland; and Heidelberg, Germany. Visit www.molecularhealth.com for more information. Contact: Gregory FCA Jessica Attanasio Associate Vice President 610-228-2112 Jessica@GregoryFCA.com
MolecularHealth Adds Chief Medical Officer to New Management Team
Press spacebar to pause and continue. Press esc to stop.